Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
75 76 Next >
News headline image
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts ↗
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
News headline image
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings ↗
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
News headline image
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government ↗
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
News headline image
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases ↗
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
News headline image
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
From AstraZeneca
Via Business Wire
News headline image
P/E Ratio Insights for AstraZeneca ↗
 
Via Benzinga
News headline image
AstraZeneca Plc (AZN) Q2 2023 Earnings Call Transcript ↗
AZN earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories ↗
Benzinga 
Via Benzinga
Topics Supply Chain
News headline image
AstraZeneca Under Legal Lens, Faces Two COVID-19 Vaccine Lawsuits In London ↗
AstraZeneca Plc (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, is reportedly under legal scrutiny as it faces two lawsuits related to its  
Via Benzinga
Topics Lawsuit
News headline image
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus ↗
Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that... 
Via Benzinga
News headline image
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late ↗
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
News headline image
AstraZeneca Earnings Preview ↗
 
Via Benzinga
News headline image
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth ↗
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
News headline image
The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023 ↗
These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development. 
Via InvestorPlace
News headline image
AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
From AstraZeneca
Via Business Wire
News headline image
Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version ↗
Chinese pharma firms are reportedly working on producing local equivalents of advanced weight-loss medications, challenging Western pharmaceutical giants in a  
Via Benzinga
News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
Is This Blue Chip Dividend Stock a Buy for Growth Investors? ↗
The British drugmaker has been a winner for shareholders in recent years. 
Via The Motley Fool
News headline image
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations ↗
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize... 
Via Talk Markets
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Via Investor Brand Network
News headline image
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
News headline image
3 Pharma Stocks to Buy for Their Promising Progress ↗
Explore the top promising pharma stocks, leading the proverbial marathon towards transformative healthcare. 
Via InvestorPlace
News headline image
AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization ↗
Earlier today, AstraZeneca plc (NASDAQ: AZN)  
Via Benzinga
News headline image
European Stock Futures Surge After ECB Meeting ↗
In the fast-paced world of finance, hot futures have emerged as a dynamic and alluring investment opportunity. 
Via Talk Markets
News headline image
iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up ↗
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has  
Via Benzinga
News headline image
US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon ↗
Stocks appear to have shaken off Thursday's negativity and are positioned for a rebound on upbeat earnings. 
Via Benzinga
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
From AstraZeneca
Via Business Wire
News headline image
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports ↗
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss... 
Via Benzinga
News headline image
Earnings Scheduled For July 28, 2023 ↗
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.